Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy
- PMID: 15731532
- DOI: 10.1253/circj.69.283
Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy
Abstract
Background: Efficacy and safety assessments for carperitide (alpha-human atrial natriuretic peptide) in previous clinical trials have not mentioned its limitations in practice as therapy for acute heart failure.
Methods and results: A 6-year prospective open-label registry analysis was conducted in the 'real world' of therapy for 3,777 patients with acute heart failure (male 57%, median age 73) treated with 0.085 microg . kg(-1) . min(-1) (median, interquartile 0.05-0.1) of carperitide for 65 h (median, interquartile 22-142); 51% were assessed as class III or IV according to the Killip classification; 82% of the patients were assessed as clinically improved after carperitide treatment. The efficacy limitation was related to the underlying disease (acute myocardial infarction), severity of Killip classification (Class IV), and renal function disturbance. The efficacy was significantly higher in patients with decompensated chronic heart failure (ie, cardiomyopathy, valvular diseases, and hypertensive heart disease). Incidence of adverse events was 16.9%, the most frequent being blood pressure lowering (9.5%), which occurred in the first 3 h of infusion, with 96% of patients recovering or improving without specific treatment. Logistic regression analysis revealed that factors predicting mortality (11.4%) during 7 days of follow-up were age, Killip classification, renal function disturbance, low blood pressure and use of vasopressors.
Conclusion: The clinical condition improved in 82% of patients treated with carperitide. Based on these findings, minute strategy will be established for carperitide therapy within the strata of patient characteristics that may predict the prognosis.
Similar articles
-
Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart Failure Study.Circ J. 2008 Nov;72(11):1777-86. doi: 10.1253/circj.cj-07-0760. Epub 2008 Oct 3. Circ J. 2008. PMID: 18832779 Clinical Trial.
-
Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study.Circ J. 2008 Nov;72(11):1787-93. doi: 10.1253/circj.cj-08-0130. Epub 2008 Sep 24. Circ J. 2008. PMID: 18812677 Clinical Trial.
-
Predictors of responders for low-dose carperitide monotherapy in patients with acute heart failure.Heart Vessels. 2020 Jan;35(1):59-68. doi: 10.1007/s00380-019-01450-w. Epub 2019 Jun 21. Heart Vessels. 2020. PMID: 31227874
-
Comparison of salt with low-dose furosemide and carperitide for treating acute decompensated heart failure: a single-center retrospective cohort study.Heart Vessels. 2017 Apr;32(4):419-427. doi: 10.1007/s00380-016-0883-1. Epub 2016 Jul 28. Heart Vessels. 2017. PMID: 27469321
-
Predictors of Worsening Renal Function in Patients With Acute Decompensated Heart Failure Treated by Low-Dose Carperitide.Circ J. 2016;80(2):418-25. doi: 10.1253/circj.CJ-15-0928. Epub 2015 Dec 15. Circ J. 2016. PMID: 26667591
Cited by
-
Data Analysis and Systematic Scoping Review on the Pathogenesis and Modalities of Treatment of Thyroid Storm Complicated with Myocardial Involvement and Shock.Diagnostics (Basel). 2023 Sep 23;13(19):3028. doi: 10.3390/diagnostics13193028. Diagnostics (Basel). 2023. PMID: 37835772 Free PMC article. Review.
-
Taipan Natriuretic Peptides Are Potent and Selective Agonists for the Natriuretic Peptide Receptor A.Molecules. 2023 Mar 29;28(7):3063. doi: 10.3390/molecules28073063. Molecules. 2023. PMID: 37049825 Free PMC article.
-
DNA Methylation of the Natriuretic Peptide System Genes and Ischemic Stroke: Gene-Based and Gene Set Analyses.Neurol Genet. 2022 May 11;8(3):e679. doi: 10.1212/NXG.0000000000000679. eCollection 2022 Jun. Neurol Genet. 2022. PMID: 35620136 Free PMC article.
-
Serum Atrial Natriuretic Peptide, NPPA Promoter Methylation, and Cardiovascular Disease: A 10-year Follow-Up Study in Chinese Adults.Glob Heart. 2022 Apr 7;17(1):27. doi: 10.5334/gh.1116. eCollection 2022. Glob Heart. 2022. PMID: 35586748 Free PMC article.
-
Extracellular Vesicles and the Inflammasome: An Intricate Network Sustaining Chemoresistance.Front Oncol. 2022 Apr 22;12:888135. doi: 10.3389/fonc.2022.888135. eCollection 2022. Front Oncol. 2022. PMID: 35530309 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous